Research PaperJournal of Pharmacology and PharmacotherapeuticsVol. 12 | Issue 1 | 2021 | pp. 10–13Open access
Comparison of Intravenous Ramosetron and Ondansetron as Prophylaxis for Postoperative Nausea and Vomiting following General Anesthesia
- 1,
- 2,
- 2*,
- 2
- 1 Department of Anaesthesia, Sardar Patel Medical College, Bikaner, Rajasthan, India.
- 2 Department of Anaesthesiology, Goa Medical College, Bambolim, Goa, India.
Published in Journal of Pharmacology and Pharmacotherapeutics
Correspondence: Roopesh Sureshan
Department of Anaesthesiology, Goa Medical College, Bambolim, Goa, India.
Email: roopesh14488@gmail.com
Copyright: © 2021 Manuscript Technomedia LLP. This is an open access article.
- Published:
- Jan 1, 2021
- Received:
- Dec 16, 2020
- Accepted:
- Mar 17, 2021
How to cite
Opneja, S., Souza, S. A. D., Sureshan, R., & Ghoshal, P. (2021). Comparison of Intravenous Ramosetron and Ondansetron as Prophylaxis for Postoperative Nausea and Vomiting following General Anesthesia. Journal of Pharmacology and Pharmacotherapeutics, 12(1), 10–13. https://doi.org/10.4103/jpp.JPP_163_20
Abstract
Objective: To compare the efficacy and side effects of 5HT3 antagonists, ramosetron, and ondansetron as prophylaxis for postoperative nausea and vomiting (PONV) following general anesthesia.
Materials and Methods: One hundred and ten patients of the American Society of Anesthesiology Grade I–II, between the age group of 18 to 60 years weighing 40 to 70 kg, undergoing general anesthesia were studied. Group 1 received ramosetron 0.3 mg intravenous (IV) and Group 2 received ondansetron 8 mg IV 15 min before the end of surgery. The incidence of PONV, need for rescue antiemetic, and side effects were evaluated in both the groups. QTc interval prolongation was also evaluated in both the groups by taking electrocardiograms at regular intervals.
Results: This study showed that there was no statistically significant difference in the incidence of PONV between the ondansetron group and the ramosetron group during the first 24 h after surgery. For PONV score of ≥2 during the first 6 h, the incidence was 3.59% and 1.81% for ramosetron and ondansetron, respectively, and during 6–24 h, the incidence was 1.81% for both the drugs.
Conclusion: IV ramosetron 0.3 mg is as effective as IV ondansetron 8 mg in preventing PONV in patients undergoing general anesthesia.
Keywords
Subject
Article metadata
| Title | Comparison of Intravenous Ramosetron and Ondansetron as Prophylaxis for Postoperative Nausea and Vomiting following General Anesthesia |
|---|---|
| Authors | Sonali Opneja; Shirley Ann D Souza; Roopesh Sureshan; Pabitra Ghoshal |
| Affiliations | Department of Anaesthesia, Sardar Patel Medical College, Bikaner, Rajasthan, India.; Department of Anaesthesiology, Goa Medical College, Bambolim, Goa, India. |
| Corresponding author | roopesh14488@gmail.com |
| Journal | Journal of Pharmacology and Pharmacotherapeutics |
| Volume / Issue | Vol. 12, Issue 1 (2021) |
Also in this issue
- Efficacy and Safety Comparison between Pioglitazone and Linagliptin in Combination with Metformin among Patients with Type 2 Diabetes Mellitus: A Meta‑Analysis of Randomized Controlled Trialspp. 1–9
- Effect of HMG-Co-A Reductase Inhibitors on Cardiac Autonomic Neuropathy in Diabetic Patientspp. 14–19
- Antibacterial Use in Admitted Patients of a Super Speciality Hospital in Western Indiapp. 20–22
- Protamine-Induced Hypotension and Pulmonary Arterial Hypertensionpp. 23–25
- Relugolix: A Novel Gonadotropin‑Releasing Hormone Antagonist for Prostate Cancerpp. 26–28
Readers Also Viewed
Development and Validation of UV/visible Spectrophotometric Method for Estimation of Piroxicam from Bulk and Formulation
Sandip Mohan Honmane, Kunal Rajaram Yadav, Yuvraj Dilip Dange
Apr 23, 2025
Effects of Artificial Intelligence on Academic Performance of Library and Information Science University Students: A Meta-Analysis (2023-2025)
Kayode Sunday John Dada
Aug 6, 2026
Bridging Innovation and Impact: A Multidisciplinary Approach to Contemporary Research Challenges
Mueen Ahmed KK
Aug 11, 2026